YKL-40 Neutralizing Antibody Radiotherapy Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting YKL-40 lack specificity and effectiveness in inhibiting tumor growth, leading to inadequate treatment outcomes for ovarian cancer and other cancers with high YKL-40 expression, particularly in advanced stages where treatment options are limited and often ineffective.
Innovation Solution
An isolated neutralizing antibody specifically binding to YKL-40 is optimized with modified antigen recognition regions and conjugated with a metal chelating group, then labeled with radioactive nuclides like lutetium-177 or actinium-225 to form a targeted radiotherapy complex for enhanced specificity and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibodies targeting YKL-40 are used, then treatment can be provided, but the antibodies lack specificity and fail to effectively inhibit tumor growth
Solution Approach 1:
The antibody sequence parameters were optimized by modifying the CDR regions (specifically VH CDR1: GYTFPNYGMN, VH CDR2: WINTYTGEPTYTVDFKG, VH CDR3: ARSFYGTNGFDY, VL CDR1: KASENVGTYVS, VL CDR2: GASNRYI, VL CDR3: GQSYSYPPT) to enhance binding affinity and specificity for YKL-40, directly resolving the contradiction between effectiveness and specificity
Solution Approach 2:
The patent creates a composite structure by conjugating the optimized antibody with metal chelating groups (such as DOTA, NOTA, DTPA) to form antibody-chelate complexes, which can then bind radioactive isotopes. This composite approach enhances both the specificity of YKL-40 binding and the therapeutic effectiveness through targeted radiotherapy
2Productivity
If conventional chemotherapy and surgery are applied, then initial response can be achieved, but treatment resistance develops and recurrence occurs
Solution Approach 1:
The optimized antibody complex enables self-targeting to YKL-40-expressing cancer cells through its high-specificity binding capability. The antibody automatically accumulates at tumor sites and delivers therapeutic effect without requiring external guidance, while the radioactive isotopes provide sustained therapeutic action that overcomes chemotherapy resistance
Solution Approach 2:
The antibody-chelate-radioisotope complex serves as an intermediary carrier that specifically transports radioactive therapeutic agents to YKL-40-expressing tumor cells. This mediator approach allows precise delivery of high doses of radiation directly to cancer cells while sparing healthy tissues, thereby improving long-term treatment effectiveness and reducing resistance development
3Adaptability or versatility
If advanced ovarian cancer is treated with second surgery and chemotherapy, then treatment is attempted, but effectiveness is minimal and follow-up strategies are limited
Solution Approach 1:
The optimized antibody complex serves multiple functions: it acts as a diagnostic agent for imaging YKL-40-expressing tumors, a therapeutic agent for targeted radiotherapy, and a prognostic indicator for monitoring treatment response. This multi-functionality provides a comprehensive treatment strategy for advanced ovarian cancer that overcomes the limitations of conventional single-modality approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibody complex effectively binds to YKL-40-expressing cancer cells, accumulates in tumor sites for diagnostic imaging, and significantly inhibits tumor growth, offering a more effective treatment strategy for cancers with high YKL-40 expression.
Implementation Method 1
after conjugating with the metal chelating group, the conjugated antibody complex (or the antibody complex) is then labeled with a radioactive metal nuclide such as lutetium-177 (Lu-177) and actinium-225 (Ac-225)
Data Source
AI summary
Disclosed herein an isolated neutralizing antibody, which is capable of specifically binding to chitinase-3-like protein-1 (YKL-40) and uses thereof. The neutralizing antibody can further conjugate with a metal chelator to form an antibody complex. Further, labeling the antibody complex with a radioactive metal nuclide results in formation of a radioactive antibody complex, which can be used as a contrast agent and treatment for YKL-40 over-expression-related diseases. The radioactive antibody complex can specifically bind to YKL-40, and can be used for diagnosis and the preparation of the use of the treatment for cancers related to YKL-40 over-expression.